An Efficient One-pot Synthesis of Certain Stereoselective Spiro[pyrazole-4,5′-isoxazoline]-5-one Derivatives: In vitro Evaluation of Antitumor Activities, Molecular Docking and In silico ADME Predictions

Abstract

Alibrary of novel spiro[pyrazole-4,5′-isoxazoline]-5-one derivatives were designed and synthesized using a concise and efficient one-pot reaction protocol through 1,3-dipolar cycloaddition between 4-benzylidene-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one and chlorooximes. The synthesized derivatives were elucidated and characterized based on their spectroscopic data, including infrared spectrometry(IR), ¹H NMR, ¹³C NMR, and elemental and mass spectral analysis. The synthesized compounds were evaluated for their antitumor inhibition potency against four human cancer cell lines, including human prostatic adenocarcinoma (PC3), human colorectal carcinoma(HCT116), human liver hepatocellular carcinoma(HepG2) and breast adenocarcinoma (MCF7). The outcomes were compared with the standard reference drug Doxorubicin. Among the synthesized chlorooximes, compounds 6d and 6e were the most active compounds on all cell lines. The spiro[pyrazole-4,5′-isoxazoline]-5-one derivatives 7a and 7c were active on the HepG2 liver cancer cell line. In comparison, compounds 7f and 7g were moderately active on the MCF7 cell line. The structure-activity relationship was explored for the synthesized compounds. Besides, in silico analysis of physicochemical, adsorption, distribution, metabolism, excretion and toxicity(ADMET) properties were done to determine the potential capacity of drug candidates. Molecular docking study onto the epidermal growth factor(EGF) tyrosine kinase receptor(3POZ) was done for the most active compounds to validate the reliability of in vitro anticancer screenings.

Keywords

Spiroisoxazoline / Pyrazole / Chlrooxime / 1,3-Dipolar cycloaddition / Antitumor / Molecular docking

References

[1] Chauhan A, Sharma P, Kaushik N. Int. J. ChemTech Res., 2011, 3(1): 11.

[2] Brogden R N. Drugs, 198, 32(4): 60.

[3] Kasiotis K M, Tzanetou E N, Haroutounian S A. Frontiers in Chemistry, 2014, 2: 78.

[4] Kumar V, Kaur K, Gupta G K, Sharma A K. European Journal of Medicinal Chemistry, 2013, 69: 735.

[5] Sondhi S M, Jain S, Dinodia M, Shukla R, Raghubir R. Bioorganic & Medicinal Chemistry, 2007, 15(10): 3334.

[6] Palaska E, Aytemir M, Uzbay I T, Erol D. European Journal of Medicinal Chemistry, 2001, 36(6): 539.

[7] Ma R, Zhu J, Liu J, Chen L, Shen X, Jiang H, Li J. Molecules, 2010, 15(5): 3593.

[8] Ribeiro C J, Rodrigues C M, Moreira R, Santos M M. Pharmaceuticals, 201, 9(2): 25.

[9] Khazir J, Singh P P, Reddy D M, Hyder I, Shafi S, Sawant S, Chashoo G, Mahajan A, Alam M, Saxena A. European Journal of Medicinal Chemistry, 2013, 63: 279.

[10] Das P, Boone S, Mitra D, Turner L, Tandon R, Raucher D, Hamme A T. RSC Advances, 2020, 10(50): 30223.

[11] Karale B, Gadhave A. Indian Journal of Heterocyclic Chemistry, 2010, 19(4): 389.

[12] Duffy J. L., Bao J., Ondeyka D. L., Tyagarajan S., Shao P., Ye F., Katipally R., Finke P. E., Zang Y., Plotkin M. A., Patent WO 2011/146324, 2011

[13] Zhang P-Z, Li X-L, Chen H, Li Y-N, Wang R. Tetrahedron Letters, 2007, 48(44): 7813.

[14] Zhu S, Shi S, Gerritz S W. Tetrahedron Letters, 2011, 52(31): 4001.

[15] Singh R., Goff D., Partridge J. J., Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection, Patent US-2004266840-A1, 2006

[16] Hassner A. Synthesis of Heterocycles via Cycloadditions I, Vol. 12, 2008, Berlin Heidelberg: Springer, Verlag.

[17] Namboothiri I., Rastogi N., Springer, Berlin, Germany, 2008, 1

[18] Sammelson R E, Gurusinghe C D, Kurth J M, Olmstead M M, Kurth M J. Journal of Organic Chemistry, 2002, 67(3): 876.

[19] Yazdani H, Bazgir A. Synthesis, 2019, 51(07): 1669.

[20] Masumoto E, Shirouzu E, Kashige N, Okabe-Nakahara F, Miake F, Yamagata K, Maruoka H. Heterocycles, 2018, 96(7): 1289.

[21] Outahar F, Moumou M, Hannioui A, Rakib E M, El Ammari L, Saadi M, Akssira M. Tetrahedron Letters, 2020, 61(42): 152409.

[22] Bora D., Kaushal A., Shankaraiah N., European Journal of Medicinal Chemistry, 2021, 113263

[23] Madhuswapnaja K. J., Yennam S., Chavali M., Chemistry of Biologically Potent Natural Products and Synthetic Compounds, 2021, 155

[24] Yu S, Qin D, Shangary S, Chen J, Wang G, Ding K, McEachern D, Qiu S, Nikolovska-Coleska Z, Miller R. Journal of Medicinal Chemistry, 2009, 52(24): 7970.

[25] Ewies E F, El-Hussieny M, El-Sayed N F, Ali M M, Mahmoud A E. Phosphorus, Sulfur, and Silicon and the Related Elements, 201, 191(7): 1000.

[26] Boulos L S, Ewies E F, Fahmy A F, Mohram M E. Phosphorus, Sulfur, and Silicon and the Related Elements, 2013, 188(6): 790.

[27] Ibrahim N M, Yosef H A, Ewies E F, Mahran M R, Ali M M, Mahmoud A E. Journal of the Brazilian Chemical Society, 2015, 26(6): 1086.

[28] Ewies E F, El-Shehry M F, Boulos L S. Int. J. ChemTech Res., 2015, 7: 2506.

[29] Cohen J B. A Class-book of Organic Chemistry, Vol.1, 1920, London: Macmillan and Co., Limited

[30] Jiang K M, Zhang J Q, Jin Y, Lin J. Asian J. Org. Chem., 2017, 6: 1620.

[31] Franke A., Justus Liebigs Ann. Chem., 1978, 717

[32] Azizian J, Jadidi K, Mehrdad M, Sarrafi Y. Synth. Commun., 2000, 30: 2309.

[33] Liu K-C, Shelton B R, Howe R K. Journal of Organic Chemistry, 1980, 45(19): 3916.

[34] Mosmann T. J. Immunological Methods, 1983, 65(1/2): 55.

[35] Irmer D, Funk J, Blaukat A. Oncogene, 2007, 26(39): 5693.

[36] Berasain C, Avila M A. Journal of Gastroenterology, 2014, 49(1): 9.

[37] Aertgeerts K, Skene R, Yano J, Sang B-C, Zou H, Snell G, Jennings A, Iwamoto K, Habuka N, Hirokawa A. Journal of Biological Chemistry, 2011, 286(21): 18756.

[38] Risitano F, Grassi G, Foti F. Heterocycles, 2003, 60(4): 857.

[39] Ribeiro C J, Amaral J D, Rodrigues C M, Moreira R, Santos M M. Bioorganic & Medicinal chemistry, 2014, 22(1): 577.

[40] Phillips A M F, Pombeiro A J, Kopylovich M N. ChemCatChem, 2017, 9(2): 217.

[41] Wheeldon I, Minteer S D, Banta S, Barton S C, Atanassov P, Sigman M. Nature Chemistry, 201, 8(4): 299.

[42] Zhao M Y, Abraham M H, Le J, Hersey A, Luscombe C N, Beck G, Sherborne B, Cooper I. Pharm. Res., 2002, 19: 1446.

[43] Veber D F, Johnson S R, Cheng H-Y, Smith B R, Ward K W, Kopple K D. Journal of Medicinal Chemistry, 2002, 45(12): 2615.